Abstract
Efforts to develop and refine percutaneous approaches to cardiac valve repair and replacement have advanced rapidly over the past several years, having exceeded even the most optimistic expectations. New innovations have been predominantly directed toward the most frequent form of valvular heart disease (VHD) in the industrialized world; aortic stenosis (AS). Approximately 250,000 transcatheter aortic valve implantation (TAVI) procedures have been done so far addressing this significant medical need.
Because of the predominance of degenerative etiologies, the prevalence of VHD increases markedly in population above the age of 65 years, in particular with regard to severe AS. As the populations of the industrialized countries continue to be older, the need for less invasive and safer methods of treating severe AS will continue to grow.
In this review we provide comprehensive and up-to-date overview of TAVI in current clinical practice. We have also addressed dilemmas and unanswered questions related to TAVI procedures in different groups of patients and highlighted opportunities and trends related to future TAVI implementation.
Keywords: Aortic stenosis, TAVI, future trends, cardiac valve, heart disease, aortic stenosis.
Current Pharmaceutical Design
Title:Percutaneous Treatment of Aortic Valve Disease: Contemporary Overview and Future Trends
Volume: 23 Issue: 31
Author(s): Marko Banovic*, Jozef Bartunek, Serge D. Nikolic, Vladan Vukcevic, Srdjan Aleksandric and Bernard Iung
Affiliation:
- Cardiology Department, University Clinical Center of Serbia, Belgrade,Serbia
Keywords: Aortic stenosis, TAVI, future trends, cardiac valve, heart disease, aortic stenosis.
Abstract: Efforts to develop and refine percutaneous approaches to cardiac valve repair and replacement have advanced rapidly over the past several years, having exceeded even the most optimistic expectations. New innovations have been predominantly directed toward the most frequent form of valvular heart disease (VHD) in the industrialized world; aortic stenosis (AS). Approximately 250,000 transcatheter aortic valve implantation (TAVI) procedures have been done so far addressing this significant medical need.
Because of the predominance of degenerative etiologies, the prevalence of VHD increases markedly in population above the age of 65 years, in particular with regard to severe AS. As the populations of the industrialized countries continue to be older, the need for less invasive and safer methods of treating severe AS will continue to grow.
In this review we provide comprehensive and up-to-date overview of TAVI in current clinical practice. We have also addressed dilemmas and unanswered questions related to TAVI procedures in different groups of patients and highlighted opportunities and trends related to future TAVI implementation.
Export Options
About this article
Cite this article as:
Banovic Marko *, Bartunek Jozef , Nikolic D. Serge , Vukcevic Vladan , Aleksandric Srdjan and Iung Bernard , Percutaneous Treatment of Aortic Valve Disease: Contemporary Overview and Future Trends, Current Pharmaceutical Design 2017; 23 (31) . https://dx.doi.org/10.2174/1381612822666161018162022
DOI https://dx.doi.org/10.2174/1381612822666161018162022 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Screening for Rare Genetic Variants Associated with Atherosclerosis: Opportunity for Personalized Medicine
Current Vascular Pharmacology Segmentation of Short Axis CMR Images Using Hybrid Method
Current Medical Imaging Implications of Nanotechnology in Healthcare
Nanoscience & Nanotechnology-Asia Biomarkers in Post-stroke Depression
Current Neurovascular Research Inhibition of Transcription Factors by Plant-Derived Compounds and their Implications in Inflammation and Cancer
Current Pharmaceutical Design Molecular Targets and Natural Compounds in Drug Development for the Treatment of Inflammatory Pain
Current Drug Targets Current Advances in the Treatment of Parkinsons Disease with Stem Cells
Current Neurovascular Research Ultrasound Contrast Agents: Updated Data on Safety Profile
Current Pharmaceutical Design Effects of Biologic Agents and Other Disease-Modifying Antirheumatic Drugs on Cardiovascular Outcomes in Psoriasis and Psoriatic Arthritis: A Systematic Review
Current Pharmaceutical Design Preface [Hot Topic:Inflammatory Markers and Mediators: Emerging Therapeutic Targets in Diabetes, Cardiovascular and Metabolic Disorders (Guest Editor: Samuel Dagogo-Jack, MD)].
Current Drug Targets Editorial (Hot Topic: Vitamin D Deficiency and Critical Illness)
Inflammation & Allergy - Drug Targets (Discontinued) Fine Tuning of PPAR Ligands for Type 2 Diabetes and Metabolic Syndrome
Mini-Reviews in Medicinal Chemistry Targeting Cyclooxygenase and Nitric Oxide Pathway Cross-Talk: A New Signal Transduction Pathway for Developing More Effective Anti- Inflammatory Drugs
Current Signal Transduction Therapy Preface [Hot topic: Antithrombotic Agents Executive Editor : Ho-Sam Ahn ]
Current Pharmaceutical Design Biomarkers of Asthma: Recent Patents from 2009-2011
Recent Patents on Biomarkers Combinatorial Library Synthesis of Antioxidant Compounds
Combinatorial Chemistry & High Throughput Screening The Therapeutic Potential of Hepatocyte Growth Factor for Myocardial Infarction and Heart Failure
Current Pharmaceutical Design An Artificial Immune Network Based Algorithm for Diabetes Diagnosis
Protein & Peptide Letters Opioid-induced Cardioprotection
Current Pharmaceutical Design Fondaparinux: Pharmacology and Clinical Experience in Cardiovascular Medicine
Mini-Reviews in Medicinal Chemistry